Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer

Tatsuo Matsuda, Hiroya Takeuchi, Toshiharu Sakurai, Shuhei Mayanagi, Eisuke Booka, Tomonobu Fujita, Hajime Higuchi, Junichi Taguchi, Yasuo Hamamoto, Hiromasa Takaishi, Hirofumi Kawakubo, Masato Okamoto, Makoto Sunamura, Yutaka Kawakami, Yuukou Kitagawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the present study, the immune response to Wilms tumor gene 1 (WT1) peptide-pulsed dendritic cell (DC) vaccination combined with docetaxel (DCDOC) in advanced esophageal cancer patients who had already received first-line chemotherapy was investigated. Ten HLA-A*2402 patients were treated with docetaxel (50 mg/m2) on day 1 and WT1 peptide-pulsed DC vaccination (1x107 cells) on days 15 and 22 (repeated every 4 weeks for 3 cycles). The delayed-type hypersensitivity skin test, HLA tetramer assay and interferon-γ enzyme-linked immunospot (ELISPOT) assay were used to evaluate the induction of a WT1-specific immune response. Median overall survival was 5 months (range, 1.1-11.6). The clinical effect of DCDOC therapy was not observed and only 1 patient could complete the protocol therapy. Disease progression was observed in 9 patients and 1 patient succumbed to fatality during the second cycle of therapy. As a pilot study, it was not possible to evaluate the safety of WT1 peptide-pulsed DCDOC therapy for esophageal squamous cell cancer. However, a WT1-specific response in 6 patients, as indicated by the ELISPOT or HLA/WT1-tetramer assay, was demonstrated. The results suggested that the positive immune response had significant relevance on the low percentage of CD11b+ and CD66b+ granulocytic myeloid-derived suppressor cells in CD15+ cells. Furthermore, DCDOC elicited a WT1-specific immune response regardless of the myelosuppression associated with docetaxel. The present findings support future studies and further work to assess DCDOC as an adjuvant therapy for esophageal cancer will be performed. The present clinical trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry on November 11th, 2011, no. UMIN000006704.

Original languageEnglish
Pages (from-to)1348-1356
Number of pages9
JournalOncology Letters
Volume16
Issue number1
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

docetaxel
Wilms' Tumor Genes
Wilms Tumor
Esophageal Neoplasms
Dendritic Cells
Vaccination
Peptides
Clinical Trials
Therapeutics
Enzyme-Linked Immunospot Assay
Squamous Cell Neoplasms
HLA-A Antigens
Information Services
Delayed Hypersensitivity
Skin Tests
Interferons
Registries
Disease Progression

Keywords

  • Dendritic cell vaccination
  • Docetaxel
  • Esophageal cancer
  • Immunotherapy
  • Peptide
  • WT1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. / Matsuda, Tatsuo; Takeuchi, Hiroya; Sakurai, Toshiharu; Mayanagi, Shuhei; Booka, Eisuke; Fujita, Tomonobu; Higuchi, Hajime; Taguchi, Junichi; Hamamoto, Yasuo; Takaishi, Hiromasa; Kawakubo, Hirofumi; Okamoto, Masato; Sunamura, Makoto; Kawakami, Yutaka; Kitagawa, Yuukou.

In: Oncology Letters, Vol. 16, No. 1, 01.07.2018, p. 1348-1356.

Research output: Contribution to journalArticle

Matsuda, T, Takeuchi, H, Sakurai, T, Mayanagi, S, Booka, E, Fujita, T, Higuchi, H, Taguchi, J, Hamamoto, Y, Takaishi, H, Kawakubo, H, Okamoto, M, Sunamura, M, Kawakami, Y & Kitagawa, Y 2018, 'Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer', Oncology Letters, vol. 16, no. 1, pp. 1348-1356. https://doi.org/10.3892/ol.2018.8734
Matsuda, Tatsuo ; Takeuchi, Hiroya ; Sakurai, Toshiharu ; Mayanagi, Shuhei ; Booka, Eisuke ; Fujita, Tomonobu ; Higuchi, Hajime ; Taguchi, Junichi ; Hamamoto, Yasuo ; Takaishi, Hiromasa ; Kawakubo, Hirofumi ; Okamoto, Masato ; Sunamura, Makoto ; Kawakami, Yutaka ; Kitagawa, Yuukou. / Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. In: Oncology Letters. 2018 ; Vol. 16, No. 1. pp. 1348-1356.
@article{78ad3da0e09a42aca67c7919fc5a9730,
title = "Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer",
abstract = "In the present study, the immune response to Wilms tumor gene 1 (WT1) peptide-pulsed dendritic cell (DC) vaccination combined with docetaxel (DCDOC) in advanced esophageal cancer patients who had already received first-line chemotherapy was investigated. Ten HLA-A*2402 patients were treated with docetaxel (50 mg/m2) on day 1 and WT1 peptide-pulsed DC vaccination (1x107 cells) on days 15 and 22 (repeated every 4 weeks for 3 cycles). The delayed-type hypersensitivity skin test, HLA tetramer assay and interferon-γ enzyme-linked immunospot (ELISPOT) assay were used to evaluate the induction of a WT1-specific immune response. Median overall survival was 5 months (range, 1.1-11.6). The clinical effect of DCDOC therapy was not observed and only 1 patient could complete the protocol therapy. Disease progression was observed in 9 patients and 1 patient succumbed to fatality during the second cycle of therapy. As a pilot study, it was not possible to evaluate the safety of WT1 peptide-pulsed DCDOC therapy for esophageal squamous cell cancer. However, a WT1-specific response in 6 patients, as indicated by the ELISPOT or HLA/WT1-tetramer assay, was demonstrated. The results suggested that the positive immune response had significant relevance on the low percentage of CD11b+ and CD66b+ granulocytic myeloid-derived suppressor cells in CD15+ cells. Furthermore, DCDOC elicited a WT1-specific immune response regardless of the myelosuppression associated with docetaxel. The present findings support future studies and further work to assess DCDOC as an adjuvant therapy for esophageal cancer will be performed. The present clinical trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry on November 11th, 2011, no. UMIN000006704.",
keywords = "Dendritic cell vaccination, Docetaxel, Esophageal cancer, Immunotherapy, Peptide, WT1",
author = "Tatsuo Matsuda and Hiroya Takeuchi and Toshiharu Sakurai and Shuhei Mayanagi and Eisuke Booka and Tomonobu Fujita and Hajime Higuchi and Junichi Taguchi and Yasuo Hamamoto and Hiromasa Takaishi and Hirofumi Kawakubo and Masato Okamoto and Makoto Sunamura and Yutaka Kawakami and Yuukou Kitagawa",
year = "2018",
month = "7",
day = "1",
doi = "10.3892/ol.2018.8734",
language = "English",
volume = "16",
pages = "1348--1356",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer

AU - Matsuda, Tatsuo

AU - Takeuchi, Hiroya

AU - Sakurai, Toshiharu

AU - Mayanagi, Shuhei

AU - Booka, Eisuke

AU - Fujita, Tomonobu

AU - Higuchi, Hajime

AU - Taguchi, Junichi

AU - Hamamoto, Yasuo

AU - Takaishi, Hiromasa

AU - Kawakubo, Hirofumi

AU - Okamoto, Masato

AU - Sunamura, Makoto

AU - Kawakami, Yutaka

AU - Kitagawa, Yuukou

PY - 2018/7/1

Y1 - 2018/7/1

N2 - In the present study, the immune response to Wilms tumor gene 1 (WT1) peptide-pulsed dendritic cell (DC) vaccination combined with docetaxel (DCDOC) in advanced esophageal cancer patients who had already received first-line chemotherapy was investigated. Ten HLA-A*2402 patients were treated with docetaxel (50 mg/m2) on day 1 and WT1 peptide-pulsed DC vaccination (1x107 cells) on days 15 and 22 (repeated every 4 weeks for 3 cycles). The delayed-type hypersensitivity skin test, HLA tetramer assay and interferon-γ enzyme-linked immunospot (ELISPOT) assay were used to evaluate the induction of a WT1-specific immune response. Median overall survival was 5 months (range, 1.1-11.6). The clinical effect of DCDOC therapy was not observed and only 1 patient could complete the protocol therapy. Disease progression was observed in 9 patients and 1 patient succumbed to fatality during the second cycle of therapy. As a pilot study, it was not possible to evaluate the safety of WT1 peptide-pulsed DCDOC therapy for esophageal squamous cell cancer. However, a WT1-specific response in 6 patients, as indicated by the ELISPOT or HLA/WT1-tetramer assay, was demonstrated. The results suggested that the positive immune response had significant relevance on the low percentage of CD11b+ and CD66b+ granulocytic myeloid-derived suppressor cells in CD15+ cells. Furthermore, DCDOC elicited a WT1-specific immune response regardless of the myelosuppression associated with docetaxel. The present findings support future studies and further work to assess DCDOC as an adjuvant therapy for esophageal cancer will be performed. The present clinical trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry on November 11th, 2011, no. UMIN000006704.

AB - In the present study, the immune response to Wilms tumor gene 1 (WT1) peptide-pulsed dendritic cell (DC) vaccination combined with docetaxel (DCDOC) in advanced esophageal cancer patients who had already received first-line chemotherapy was investigated. Ten HLA-A*2402 patients were treated with docetaxel (50 mg/m2) on day 1 and WT1 peptide-pulsed DC vaccination (1x107 cells) on days 15 and 22 (repeated every 4 weeks for 3 cycles). The delayed-type hypersensitivity skin test, HLA tetramer assay and interferon-γ enzyme-linked immunospot (ELISPOT) assay were used to evaluate the induction of a WT1-specific immune response. Median overall survival was 5 months (range, 1.1-11.6). The clinical effect of DCDOC therapy was not observed and only 1 patient could complete the protocol therapy. Disease progression was observed in 9 patients and 1 patient succumbed to fatality during the second cycle of therapy. As a pilot study, it was not possible to evaluate the safety of WT1 peptide-pulsed DCDOC therapy for esophageal squamous cell cancer. However, a WT1-specific response in 6 patients, as indicated by the ELISPOT or HLA/WT1-tetramer assay, was demonstrated. The results suggested that the positive immune response had significant relevance on the low percentage of CD11b+ and CD66b+ granulocytic myeloid-derived suppressor cells in CD15+ cells. Furthermore, DCDOC elicited a WT1-specific immune response regardless of the myelosuppression associated with docetaxel. The present findings support future studies and further work to assess DCDOC as an adjuvant therapy for esophageal cancer will be performed. The present clinical trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry on November 11th, 2011, no. UMIN000006704.

KW - Dendritic cell vaccination

KW - Docetaxel

KW - Esophageal cancer

KW - Immunotherapy

KW - Peptide

KW - WT1

UR - http://www.scopus.com/inward/record.url?scp=85047601649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047601649&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.8734

DO - 10.3892/ol.2018.8734

M3 - Article

AN - SCOPUS:85047601649

VL - 16

SP - 1348

EP - 1356

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 1

ER -